These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 38062315)

  • 1. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
    Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
    Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
    Tang XY; Ding YS; Zhou T; Wang X; Yang Y
    Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.
    Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A
    Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
    Rosewell Shaw A; Suzuki M
    Front Immunol; 2018; 9():2103. PubMed ID: 30298067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
    McGrath K; Dotti G
    Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].
    Kochneva GV; Sivolobova GF; Tkacheva AV; Gorchakov AA; Kulemzin SV
    Mol Biol (Mosk); 2020; 54(1):3-16. PubMed ID: 32163385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
    Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
    Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
    Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
    Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
    Heidbuechel JPW; Engeland CE
    J Hematol Oncol; 2021 Apr; 14(1):63. PubMed ID: 33863363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses.
    Jafari M; Kadkhodazadeh M; Shapourabadi MB; Goradel NH; Shokrgozar MA; Arashkia A; Abdoli S; Sharifzadeh Z
    Front Immunol; 2022; 13():1012806. PubMed ID: 36311790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
    Gao X; Liu J; Sun R; Zhang J; Cao X; Zhang Y; Zhao M
    Ann Hematol; 2024 Aug; 103(8):2569-2589. PubMed ID: 37853078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.